Skip to content

Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing

A Randomised Multicentre Clinical Trial on the Efficacy of Flammacerium in the Treatment of Facial Burns and the Impact of Facial Burns on Psychosocial Wellbeing

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00297752
Enrollment
154
Registered
2006-03-01
Start date
2006-03-31
Completion date
2008-12-31
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

facial burns, cerium flammazine, quality of life, randomised clinical trial

Brief summary

The face is involved in 40-50% of patients with burns admitted to the Dutch Burn Centres. Scarring of the face as a consequence of burns will often have a detrimental effect on function and aesthetics, and may cause negative effects on psychosocial wellbeing. What the best treatment is for facial burns, minimising scarring, is unclear. Besides that, there is little empirical evidence regarding the impact of facial scarring on psychosocial wellbeing. In clinical practice good results are felt to be achieved by treatment of facial burns with flammacerium. To substantiate the perceived advantages of flammacerium, its efficacy is compared to flammazine, a current alternative of care. The efficacy of treatment will be assessed in a prospective randomised multicentre clinical trial. Efficacy will be analysed in terms of number of patients requiring surgery and functional and aesthetic outcome. Apart from medical outcome, this study offers the opportunity to study psychosocial problems associated with facial defects. It is still an unresolved question whether facial scarring causes more or different psychosocial problems. Therefore, self-esteem and quality of life will be examined over time, in relation to depression, posttraumatic stress symptoms and other factors, such as coping style and social support. By evaluating the efficacy of different treatment strategies, we aim to optimise the standard of care of facial burns. Furthermore, this study wants to shed more light on the psychosocial impact of facial injury. With these results psychosocial professionals will be able to focus on persons at risk and to be better able to meet a patient's personal needs.

Interventions

DRUGceriumnitrate silversulfadiazine (flammacerium)

treatment of patients with facial burns with CE-SSD

DRUGsilversulfadiazine (flammazine)

treatment of patients with facial burns with SSD

Sponsors

Dutch Burns Foundation
CollaboratorOTHER
Association of Dutch Burn Centres
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients of 18 years of age or older, competent or temporarily incompetent, who are admitted to one of the three dedicated Dutch Burn Centres with burn injuries involving the face

Exclusion criteria

* patients not seen within 24 hours postburn * patients with mental or cognitive deficits that may interfere with providing informed consent * patients with poor Dutch proficiency * patients with chemical burns

Design outcomes

Primary

MeasureTime frameDescription
Regarding the efficacy of treatment3 weekstime to wound healing
* number of patients requiring surgical excision of their facial burns6 weeksnumber of patients requiring surgical treatment for healing of facial burns
Regarding psychosocial impact:3 monthsdiscrepancy between patient and observer scar assessment
* quality of life and self esteem6 months post burnmeasurement of self esteem related to scar quality

Secondary

MeasureTime frameDescription
● quality of scar (patient and observer)12 months post burnscar assessment by patient and observer scar scale
● mimic function12 months post burnphysical examination
● scar elasticity, vascularisation and pigmentation,12 months post burnscar assessment by cutometer and dermaspectrometer
● hypertrophic surface area12 months post burnscar thickness area
● functional and/or anatomic impairments,12 months post burndescriptive analysis

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026